In a bid to help improve mental health care across Europe, the Psychedelic Access and Research European Alliance (PAREA) has launched a manifesto for the 2024...
Cybin Inc.
In the face of escalating climate, economic and mental health crises, millions are seeking legal, safe ways to experience magic mushrooms (psilocybin) and other psychoactive plant...
Results from the world’s largest study investigating the ‘naturalistic’ use of psilocybin outside of research settings have shown lasting therapeutic benefits.
The European Medicines Agency (EMA) has updated its general guidelines on the development of medicinal products for Major Depressive Disorder (MDD) to include a section on...
California could decriminalise naturally occurring psychedelics and create a framework for their therapeutic use under a new bill.
MAPS PBC has published anticipated results from its Phase 3b study that could bring MDMA-assisted therapy closer to Food and Drug Administration (FDA) approval by 2024...
A new research review has explored the use of psilocybin for the treatment of resistant depression.
In a new policy briefing for the European Medicines Agency (EMA), Psychedelic Access and Research European Alliance (PAREA) has called for an advisory body on psychedelics...
Findings from a landmark survey have revealed that people with experience using psychedelics exhibited elevated psychological well-being during the COVID-19 pandemic.
